Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
Tóm tắt
Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the prevalence and clinical associations of novel myositis autoantibodies in ILD are presented. A total of 1194 patients with ILD and 116 healthy subjects were tested for antibodies specific for Ks, Ha, Zoα, and cN1A with a line-blot assay on serum available at the time of diagnosis. Autoantibodies were demonstrated in 63 (5.3%) patients and one (0.9%) healthy control (p = 0.035). Autoantibodies were found more frequently in females (p = 0.042) and patients without a histological and/or radiological usual interstitial pneumonia (UIP; p = 0.010) and a trend towards CTD-ILDs (8.4%) was seen compared with other ILDs (4.9%; p = 0.090). The prevalence of antibodies specific for Ks, Ha, Zoα, and cN1A was, respectively, 1.3%, 2.0%, 1.4%, and 0.9% in ILD. Anti-Ha and Anti-Ks were observed in males with unclassifiable idiopathic interstitial pneumonia (unclassifiable IIP), hypersensitivity pneumonitis (HP), and various CTD-ILDs, whereas anti-cN1A was seen in females with antisynthetase syndrome (ASS), HP, and idiopathic pulmonary fibrosis (IPF). Anti-Zoα was associated with CTD-ILD (OR 2.5; 95%CI 1.11–5.61; p = 0.027). In conclusion, a relatively high prevalence of previously unknown myositis autoantibodies was found in a large cohort of various ILDs. Our results contribute to the awareness that circulating autoantibodies can be found in ILDs with or without established CTD. Whether these antibodies have to be added to the standard set of autoantibodies analysed in conventional myositis blot assays for diagnostic purposes in clinical ILD care requires further study.
Từ khóa
Tài liệu tham khảo
Moore, 2019, Idiopathic and immune-related pulmonary fibrosis: Diagnostic and therapeutic challenges, Clin. Transl. Immunol., 8, e1086, 10.1002/cti2.1086
Margaritopoulos, 2014, Interstitial Lung Disease in Systemic Sclerosis, Semin. Respir. Crit. Care Med., 35, 213, 10.1055/s-0034-1371541
Strange, 2004, Interstitial lung disease in the patient who has connective tissue disease, Clin. Chest Med., 25, 549, 10.1016/j.ccm.2004.05.009
Stevenson, 2019, Autoantibodies in interstitial lung diseases, Pathology, 51, 518, 10.1016/j.pathol.2019.03.007
Fidler, 2019, Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease, Lung, 197, 277, 10.1007/s00408-019-00212-9
Bahmer, 2016, The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD)–A practical approach for the pulmonologist, Respir. Med., 113, 80, 10.1016/j.rmed.2016.01.019
Ryerson, 2014, Predicting Survival Across Chronic Interstitial Lung Disease, Chest, 145, 723, 10.1378/chest.13-1474
Park, 2007, Prognosis of Fibrotic Interstitial Pneumonia, Am. J. Respir. Crit. Care Med., 175, 705, 10.1164/rccm.200607-912OC
Suda, 2010, Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD), Respir. Med., 104, 1527, 10.1016/j.rmed.2010.04.022
Anstrom, 2012, Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary Fibrosis, N. Engl. J. Med., 366, 1968, 10.1056/NEJMoa1113354
Bodart, 2018, Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias, Lung, 196, 329, 10.1007/s00408-018-0108-8
Fathi, 2008, Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiology, Arthritis Rheum., 59, 677, 10.1002/art.23571
Papiris, 2012, Serologic evaluation in idiopathic interstitial pneumonias, Curr. Opin. Pulm. Med., 18, 433, 10.1097/MCP.0b013e3283560840
Saketkoo, 2010, Interstitial Lung Disease in Idiopathic Inflammatory Myopathy, Curr. Rheumatol. Rev., 6, 108, 10.2174/157339710791330740
Satoh, 2017, A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy, Clin. Rev. Allergy Immunol., 52, 1, 10.1007/s12016-015-8510-y
Watanabe, 2011, Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias, Respir. Med., 105, 1238, 10.1016/j.rmed.2011.03.022
Hanke, 2009, Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients, Arthritis Res. Ther., 11, R22, 10.1186/ar2614
Lhote, R., Grenier, P., Haroche, J., Miyara, M., Boussouar, S., Mathian, A., Pha, M., Amoura, Z., and Aubart, F.C. (2019). Characterization of Interstitial Lung Disease Associated with Anti-Ribonucleoprotein Antibodies. JCR J. Clin. Rheumatol.
Nakashima, 2018, Clinical significance of myositis-specific autoantibodies, Immunol. Med., 41, 103, 10.1080/25785826.2018.1531188
Solomon, 2019, Myositis-related interstitial lung disease and antisynthetase syndrome, J. Bras Pneumol., 37, 100, 10.1590/S1806-37132011000100015
Platteel, 2019, Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients, J. Transl. Autoimmun., 2, 100013, 10.1016/j.jtauto.2019.100013
Hengstman, 2006, Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen, Ann. Rheum. Dis., 65, 242, 10.1136/ard.2005.040717
Fischer, 2009, Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia, Respir. Med., 103, 1719, 10.1016/j.rmed.2009.05.001
Nakashima, R., Imura, Y., Hosono, Y., Seto, M., Murakami, A., Watanabe, K., Handa, T., Mishima, M., Hirakata, M., and Takeuchi, T. (2014). The Multicenter Study of a New Assay for Simultaneous Detection of Multiple Anti-Aminoacyl-tRNA Synthetases in Myositis and Interstitial Pneumonia. PLoS ONE, 9.
Magro, 2006, Idiopathic Pulmonary Fibrosis Related to Endothelial Injury and Antiendothelial Cell Antibodies, Hum. Immunol., 67, 284, 10.1016/j.humimm.2006.02.026
Herbert, 2016, Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases, Ann. Rheum. Dis., 75, 696, 10.1136/annrheumdis-2014-206691
Lloyd, 2016, Cytosolic 5′-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases, Arthritis Care Res., 68, 66, 10.1002/acr.22600
Tansley, 2019, The myositis clinical phenotype associated with anti-Zo autoantibodies: A case series of nine UK patients, Rheumatology, 59, 1626, 10.1093/rheumatology/kez504
Kramp, 2016, Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis, Autoimmun. Highlights, 7, 1, 10.1007/s13317-016-0088-8
Muro, 2017, Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts, Clin. Chim. Acta, 472, 1, 10.1016/j.cca.2017.07.002
Rietveld, 2018, Autoantibodies to cytosolic 5′-nucleotidase 1A in primary Sjögren’s syndrome and systemic lupus erythematosus, Front. Immunol., 9, 1200, 10.3389/fimmu.2018.01200
Hirakata, 1999, Anti-KS: Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease, J. Immunol., 162, 2315, 10.4049/jimmunol.162.4.2315
Hamaguchi, Y., Fujimoto, M., Matsushita, T., Kaji, K., Komura, K., Hasegawa, M., Kodera, M., Muroi, E., Fujikawa, K., and Seishima, M. (2013). Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. PLoS ONE, 8.
Valesini, 1989, Clinical serological correlations in the evaluation of Sjögren’s syndrome, Clin. Exp. Rheumatol., 7, 197
Riley, 2010, Mutation of the Mitochondrial Tyrosyl-tRNA Synthetase Gene, YARS2, Causes Myopathy, Lactic Acidosis, and Sideroblastic Anemia—MLASA Syndrome, Am. J. Hum. Genet., 87, 52, 10.1016/j.ajhg.2010.06.001
Sommerville, 2017, Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy, JAMA Neurol., 74, 686, 10.1001/jamaneurol.2016.4357
Travis, 2013, An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias, Am. J. Respir. Crit. Care Med., 188, 733, 10.1164/rccm.201308-1483ST
Raghu, 2018, Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am. J. Respir. Crit. Care Med., 198, e44, 10.1164/rccm.201807-1255ST
Fischer, 2015, An official European Respiratory Society/ American Thoracic Society research statement: Interstitial pneumonia with autoimmune features behalf of the “ERS/ATS Task Force on Undifferentiated Forms of Ctd-Ild” Ers/Ats Task Force Interstitial Lung Disease, Eur. Respir. J., 10, 976, 10.1183/13993003.00150-2015
Damoiseaux, 2019, Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays, Autoimmun. Rev., 18, 293, 10.1016/j.autrev.2018.10.004
Okayasu, 2009, Nonspecific interstitial pneumonia (NSIP) associated with anti-KS antibody: Differentiation from idiopathic NSIP, Intern. Med., 48, 1301, 10.2169/internalmedicine.48.2207
Betteridge, 2007, Anti-synthetase syndrome: A new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia, Rheumatology, 46, 1005, 10.1093/rheumatology/kem045
Pluk, 2013, Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis, Ann. Neurol., 73, 397, 10.1002/ana.23822
Aiko, 2020, Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease, Respir. Investig., 58, 196, 10.1016/j.resinv.2019.12.003
Schneider, 2015, The Pulmonary Histopathology of Anti-KS Transfer RNA Synthetase Syndrome, Arch. Pathol. Lab. Med., 139, 122, 10.5858/arpa.2013-0667-OA
Felice, 2018, Sensitivity and clinical utility of the anti-cytosolic 5′-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center, Neuromuscul. Disord., 28, 660, 10.1016/j.nmd.2018.06.005
Heukels, 2019, Inflammation and immunity in IPF pathogenesis and treatment, Respir. Med., 147, 79, 10.1016/j.rmed.2018.12.015
Asai, 2019, Aberrant populations of circulating T follicular helper cells and regulatory B cells underlying idiopathic pulmonary fibrosis, Respir. Res., 20, 244, 10.1186/s12931-019-1216-6
Distler, 2019, Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease, N. Engl. J. Med., 380, 2518, 10.1056/NEJMoa1903076
Flaherty, 2019, Nintedanib in Progressive Fibrosing Interstitial Lung Diseases, N. Engl. J. Med., 381, 1718, 10.1056/NEJMoa1908681
Laurent, 2015, γ-secretase directly sheds the survival receptor BCMA from plasma cells, Nat. Commun., 6, 7333, 10.1038/ncomms8333
Camarena, 2020, Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients, Sci. Rep., 10, 1
Donahoe, M., Valentine, V.G., Chien, N., Gibson, K.F., Raval, J.S., Saul, M., Xue, J., Zhang, Y., and Duncan, S.R. (2015). Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS ONE, 17.